Axatilimab Biosimilar – Anti-CSF1R, CD115 mAb – Research Grade

Introduction

Axatilimab Biosimilar, also known as Anti-CSF1R, CD115 mAb, is a monoclonal antibody that has been developed as a potential therapeutic for various diseases. It specifically targets the CSF1R (colony stimulating factor 1 receptor) protein, also known as CD115, which plays a crucial role in the regulation of the immune system and cell proliferation. In this article, we will discuss the structure, activity, and potential applications of Axatilimab Biosimilar as a research grade antibody.

Structure of Axatilimab Biosimilar

Axatilimab Biosimilar is a recombinant humanized IgG1 monoclonal antibody, composed of two heavy chains and two light chains. The heavy chains consist of 451 amino acids, while the light chains consist of 214 amino acids. The antibody has a molecular weight of approximately 150 kDa. It is produced using advanced genetic engineering techniques, which involve the insertion of specific DNA sequences into host cells, resulting in the production of large quantities of the antibody.

Activity of Axatilimab Biosimilar

Axatilimab Biosimilar specifically targets the CSF1R protein, which is expressed on the surface of various immune cells, including macrophages, monocytes, and dendritic cells. The binding of Axatilimab Biosimilar to CSF1R inhibits its activity, leading to the suppression of immune responses and cell proliferation. This is achieved through the blockade of downstream signaling pathways, such as the PI3K/Akt and MAPK/ERK pathways, which are essential for cell survival and proliferation.

Applications of Axatilimab Biosimilar Axatilimab Biosimilar has potential applications in various diseases, including

autoimmune disorders, cancer, and inflammatory conditions. As an anti-CSF1R antibody, it has been shown to be effective in treating diseases that involve dysregulated immune responses, such as rheumatoid arthritis, multiple sclerosis, and lupus. It has also shown promising results in preclinical studies for the treatment of certain types of cancer, including breast, ovarian, and lung cancer. By inhibiting the activity of CSF1R, Axatilimab Biosimilar can reduce the number of immune cells that promote tumor growth and suppress the immune response against cancer cells.

Research Grade Antibody

Axatilimab Biosimilar is currently available as a research grade antibody, which means it is intended for use in laboratory research and not for clinical purposes. It is produced under strict quality control measures to ensure its purity, stability, and consistency. This makes it a reliable tool for scientists and researchers to study the role of CSF1R in various diseases and to develop potential therapeutic strategies.

Conclusion

In summary, Axatilimab Biosimilar is a recombinant humanized monoclonal antibody that specifically targets the CSF1R protein. Its structure, activity, and potential applications make it a promising candidate for the treatment of various diseases, particularly those involving dysregulated immune responses. As a research grade antibody, it provides a valuable tool for scientists to further understand the role of CSF1R and develop potential therapies for diseases in which it is implicated. With ongoing research and development, Axatilimab Biosimilar has the potential to become a valuable therapeutic option for patients in the future.